Kyowa Hakko USA has launched Velox, a new patented blend of its clinically studied L-Citrulline and L-Arginine.
Kyowa Hakko USA (New York City, NY) has launched Velox, a new patented blend of its clinically studied L-Citrulline and L-Arginine. The blend is marketed to support athletic performance, clinically studied to support blood arginine levels increasing power output and reducing muscle soreness. Velox also supports nitric oxide production.
Velox is supported by four U.S. patents: U.S. Patent 8,609,735, U.S. Patent 9,060,980, U.S. Patent 9,622,998, and U.S. Patent 10,052,298 titled, “Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine” which covers the use of ingredients and related compounds within the blend. The effective dose requires 1.2 grams minimum of L-Citrulline and 1.2 g of L-Arginine at a 1:1 ratio to support claims.
“With four U.S. patents and clinical studies to support it, introducing this new performance blend to the market from Kyowa Hakko strengthens our position as a company that is committed to ensuring our customers always receive efficacious, ultra-pure, high-quality ingredients, guaranteed,” said Elyse Lovett, MS, MBA, senior marketing manager of Kyowa Hakko USA Inc., in a press release.